Sarepta Therapeutics announced the appointment of Michael Severino, MD, as CEO, effective July 28, 2026. Severino most recently served as CEO of Tessera Therapeutics after previously serving as vice chairman and president of AbbVie.
“Throughout my career, I have focused on combining cutting edge science with drug development and commercialization expertise to improve the lives of patients. Sarepta’s unwavering commitment to patients and science resonates deeply with me, and I was very encouraged by the long-term data supporting our approved products, and the pre-clinical and clinical data from the siRNA pipeline programs and the potential for best-in-class treatments,” said Severino.
Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of the year. Back in February, Ingram, who served as CEO since 2017, explained the decision on an investor call, citing the need to be in California to support two immediate family members recently diagnosed with Myotonic Dystrophy Type 1, the most common form of adult muscular dystrophy. Ingram called the news “a fairly shocking and certainly ironic twist of fate” given that Sarepta inked a collaboration with Arrowhead in November 2024 to develop therapies for skeletal muscle diseases.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!